López-Hernández JC, López-Alderete J, Escamilla-Ramírez Á, Rosiles-Abonce A, Violante-Villanueva A, Gutiérrez-Romero A, Vargas-Cañas S

Language: Spanish
References: 14
Page: 47-51
PDF size: 166.27 Kb.

ABSTRACT

No abstract.

REFERENCES

1. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis,treatment and prognosis. Nat Rev Neurol. 2014;10:469–82. https://doi.org/10.1038/nrneurol.2014.121.

2. López-Hernández JC, Colunga-Lozano LE, Garcia-Trejo S, Gomez-Figueroa E, Delgado-Garcia G, Bazán-Rodríguez L, et al.Electrophysiological subtypes and associated prognosis factors of Mexican adults diagnosed with Guillain-Barré syndrome, a singlecenter experience. J Clin Neurosci Off J Neurosurg Soc Australas. 2020;80:292–7. https://doi.org/10.1016/j.jocn.2020.04.059.

3. Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions andguidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599–612. https://doi.org/10.1016/j.vaccine.2010.06.003.

4. López-Hernández J, Lisette B-R, Adib J de S, Eunice M-J, Elizabeth L-M, Erika G-L, et al. Guillain-Barré syndrome following SARS-CoV-2vaccination: Is there a real association? Neuroimmunol Reports. 2022;2:100050. https://doi.org/10.1016/j.nerep.2021.100050.

5. García-Grimshaw M, Michel-Chávez A, Vera-Zertuche JM, Galnares-Olalde JA, Hernández-Vanegas LE, Figueroa-Cucurachi M, et al.Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. Clin Immunol. 2021;230:108818.https://doi.org/10.1016/j.clim.2021.108818.

6. Asia C, Asia W. Recommended composition of influenza virus vaccines for use in the 2018–2019 northern hemisphere influenza season.Relev Epidemiol Hebd. 2018;93:133–41.

7. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka K V, et al. Electrophysiological classification of Guillain-Barrésyndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol.1998;44:780–8. https://doi.org/10.1002/ana.410440512.

8. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, et al. Guillain-Barre syndrome followingvaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol. 1979;110:105–23. https://doi.org/10.1093/oxfordjournals.aje.a112795.

9. Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasescu R, et al. Guillain-Barré Syndrome Variant Occurring after SARS-CoV-2Vaccination. Ann Neurol. 2021;90:315–8. https://doi.org/10.1002/ana.26144.

10. Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-datesystematic review of 73 cases. J Neurol. 2021;268:1133–70. https://doi.org/10.1007/s00415-020-10124-x.

11. Lahoz-Fernandez PE, Miranda-Pereira J, Fonseca-Risso I, Baleeiro Rodrigues-Silva P, Freitas-Barboza IC, Vieira-Silveira CG, et al. Guillain-Barre syndrome following COVID-19 vaccines: A scoping review. Acta Neurol Scand. 2021. https://doi.org/10.1111/ane.13575.

12. Langmuir AD, Bregman DJ, Kurland LT, Nathanson N, Victor M. An epidemiologic and clinical evaluation of Guillain-Barré syndromereported in association with the administration of swine influenza vaccines. Am J Epidemiol. 1984;119:841–79. https://doi.org/10.1093/oxfordjournals.aje.a113809.

13. Juurlink DN, Stukel TA, Kwong J, Kopp A, McGeer A, Upshur RE, et al. Guillain-Barré syndrome after influenza vaccination in adults: apopulation-based study. Arch Intern Med. 2006;166:2217–21. https://doi.org/10.1001/archinte.166.20.2217.

14. Kwong JC, Vasa PP, Campitelli MA, Hawken S, Wilson K, Rosella LC, et al. Risk of Guillain-Barré syndrome after seasonal influenzavaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis. 2013;13:769–76. https://doi.org/10.1016/S1473-3099(13)70104-X.